Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis

— Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) on the face or scalp

— Actinic keratosis is the second most common diagnosis made by dermatologists in the United States1

— In one of the largest Phase III clinical study programs2 ever conducted for a topical AK treatment, tirbanibulin demonstrated complete clearance of actinic keratosis lesions at day 57 in treated face or scalp areas in a significantly higher number of patients than with vehicle

— Klisyri has a demonstrated safety profile with no patient withdrawals due to adverse events, and a convenient 5-day application period which is the shortest of any topical treatment for AK

— This approval represents a key milestone in Almirall’s therapeutic pipeline

Source: